ONCY ONCOLYTICS BIOTECH INC
Price Chart
Executive Summary
Oncolytics Biotech announced alignment with the FDA on a randomized controlled pivotal trial design for pelareorep in metastatic squamous cell carcinoma of the anal canal (SCAC), a rare cancer with no approved therapies post-first-line treatment. The study leverages strong prior data showing improved duration of response and survival versus standard of care.
Actionable Insight
Monitor for protocol finalization and trial initiation, which could catalyze partnership interest and revaluation. Positive trial results could lead to accelerated approval with substantial commercial upside in a niche but high-need indication.
Key Facts
- FDA alignment achieved on pivotal randomized controlled trial for pelareorep in metastatic SCAC
- Study targets post-standard-of-care population with no FDA-approved options
- Prior data showed 15.5 vs 9.5 month median duration of response and 82% vs 45.7% 12-month survival vs standard of care
- Trial design may support both accelerated and full approval
- Pelareorep already has Fast Track designation for colorectal and pancreatic cancers
Financial Impact
Significant potential value creation if trial succeeds, given unmet need in rare cancer and potential for dual approval pathway
Risk Factors
- Clinical trial execution risk in a rare cancer population
- Regulatory requirements may evolve despite current alignment
- Dependence on successful enrollment and funding for trial completion
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000026 |
| Document: scacfdaalignment.htm | 0001129928-26-000026 |
| Document: 0001129928-26-000026-index-headers.html | 0001129928-26-000026 |
| Document: 0001129928-26-000026-index.html | 0001129928-26-000026 |
| Document: 0001129928-26-000026.txt | 0001129928-26-000026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
12d ago
|
8-K
| $0.9300 $0.8800 | ▼ −5.38% | ▼ −4.68% | $0.8000 (−13.98%) |
|
Jun 1, 2026
13d ago
|
8-K
| $1.06 $0.9300 | ▼ −12.26% | ▼ −12.41% | $0.8000 (−24.53%) |
|
May 22, 2026
23d ago
|
8-K
| $0.8100 $0.8100 | · 0.00% | ▼ −0.59% | $0.8000 (−1.23%) |
|
May 22, 2026
23d ago
|
Press Release
| $0.8100 $0.8100 | · 0.00% | ▼ −0.59% | $0.8000 (−1.23%) |
|
Apr 27, 2026
6w ago
|
8-K
| $0.9700 $0.9000 | ▼ −7.22% | ▼ −6.73% | $0.8000 (−17.53%) |
|
Apr 6, 2026
9w ago
|
424B5
| $0.9000 $0.9100 | ▼ −1.11% | ▲ +1.43% | $0.8000 (+11.11%) |
|
Apr 6, 2026
9w ago
|
8-K
| $0.9500 $0.9000 | ▼ −5.26% | ▼ −5.33% | $0.8000 (−15.79%) |
|
Apr 6, 2026
10w ago
|
EFFECT
| $0.9500 $0.9000 | ▲ +5.26% | ▲ +5.33% | $0.8000 (+15.79%) |
|
Apr 1, 2026
10w ago
|
S-3
| $0.9300 $0.9600 | ▼ −3.23% | ▼ −3.15% | $0.8000 (+13.98%) |
|
Mar 11, 2026
13w ago
|
Insider Cluster
| $1.01 $0.9600 | ▼ −4.95% | ▼ −3.47% | $0.8000 (−20.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access